Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 12 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2005Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibDewar, A.; Cambareri, A.; Zannettino, A.; Boog, B.; Doherty, K.; Hughes, T.; Lyons, A.
2009Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesisVandyke, K.; Dewar, A.; Farrugia, A.; Fitter, S.; To, B.; Hughes, T.; Zannettino, A.
2006Imatinib as a potential antiresorptive therapy for bone diseaseDewar, A.; Farrugia, A.; Condina, M.; To, L.; Hughes, T.; Vernon-Roberts, B.; Zannettino, A.
2010Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?Fitter, S.; Vandyke, K.; Schultz, C.; White, D.; Hughes, T.; Zannettino, A.
2013Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effectsVandyke, K.; Fitter, S.; Drew, J.; Fukumoto, S.; Schultz, C.; Sims, N.; Yeung, D.; Hughes, T.; Zannettino, A.
2008Long-term imatinib therapy promotes bone formation in CML patientsFitter, S.; Dewar, A.; Kostakis, P.; To, L.; Hughes, T.; Roberts, M.; Lynch, K.; Vernon-Roberts, B.; Zannettino, A.
2007Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Venables, A.; Zrim, S.; Zannettino, A.; Lynch, K.; Manley, P.; Hughes, T.
2005Inhibition of c-fms by imatinib - Expanding the spectrum of treatmentDewar, A.; Zannettino, A.; Hughes, T.; Lyons, A.
2009Imatinib mesylate causes growth plate closure in vivoVandyke, K.; Dewar, A.; Menicanin, D.; To, L.; Hughes, T.; Zannettino, A.; Fitter, S.
2010The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cellsEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.